ClinicaliQ Trial Snapshot
- Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer — Recruiting • Phase I • Oncology • NCT07002320.
- Treatment being tested: SX-682 (a CXCR4 inhibitor) combined with apalutamide (an androgen receptor inhibitor) in men with metastatic castration-resistant prostate cancer, aiming to overcome treatment resistance through dual mechanism inhibition.
- Patient eligibility overview: Men diagnosed with metastatic castration-resistant prostate cancer who have progressed despite standard hormone therapies, representing a population with limited therapeutic options and poor prognosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Eligibility Snapshot
- : 1. Written informed consent and be capable of cooperating with treatment. 2. Age ≥ 18 years. 3. Histologically or biochemically confirmed adenocarcinoma of the prostate and with tumour tissue accessible for research analysis for this trial. Patients who have no histological diagnosis must be willing to undergo a biopsy to prove prostate adenocarcinoma. 4. Patients recruited to phase 1 dose escalation cohorts must have biopsiable disease and consent to mandatory pre- and post-treatment biopsies (baseline and on Cycle 2 Day 1). 5. Metastatic castration-resistant prostate cancer. 6. All patients must have documented resistance to 1 prior next generation antiandrogen therapy (NAAT) defined as: For phase 1 and phase 2 Cohorts: Patients who have progressed after either enzalutamide, Apalutamide or darolutamide (having received a minimum of 12-weeks of enzalutamide, Apalutamide or darolutamide) will enter phase 1 or phase 2 cohorts directly. Patients that have previously received abiraterone but not an AR antagonist should receive a lead-in with Apalutamide on trial and receive the combination on progression through the lead-in. 7. Documented prostate cancer progression as assessed by the investigator with RECIST v1.1 and PCWG3 criteria (Section 3.5) with at least two of the following criteria: 1. Progression of soft…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.